UK Markets closed

Transgene SA (0OCQ.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
2.3300+0.0700 (+3.10%)
At close: 08:48AM BST
Full screen
Previous close2.2600
Open2.3400
Bid0.0000 x 0
Ask0.0000 x 0
Day's range2.3300 - 2.3400
52-week range2.3300 - 2.3400
Volume184
Avg. volumeN/A
Market cap145.331M
Beta (5Y monthly)0.85
PE ratio (TTM)N/A
EPS (TTM)-0.3260
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® platform) at ASCO 2022

    STRASBOURG, France, May 27, 2022--Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that an abstract reporting preliminary data from the two Phase I trials assessing TG4050, its individualized neoantigen cancer vaccine, has been selected for a poster presentation at the American Society of Clinical Oncology (ASCO) annual meeting. The conference will be held online and in-person in Chica

  • Business Wire

    Transgene’s Combined General Meeting of May 25, 2022

    STRASBOURG, France, May 25, 2022--Regulatory News: The Combined Ordinary and Extraordinary General Meeting of Transgene’s (Paris:TNG) shareholders was held today (May 25, 2022) at 10:00 a.m. at the Company’s headquarters (400 boulevard Gonthier d’Andernach – Parc d’Innovation – 67400 Illkirch-Graffenstaden, France).

  • Business Wire

    Transgene Announces Upcoming Investor Meetings

    STRASBOURG, France, May 17, 2022--Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces that Management will participate in the upcoming investor events set out below: